Skip to content
Est. 1998 proudly celebrating our 27th year of championing American business
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

LIFECORE BIOMEDICAL, INC. \DE\

$5.57 -1.07% NASDAQ: LFCR · 15-min delayed
  • CHASKA, Minnesota
  • Public · NASDAQ: LFCR
  • 382 employees
$211.2MMarket cap
$557.6MRevenue · FY2019
-$38.7MNet income
382Employees
LFCRNASDAQ
1996IPO

About LIFECORE BIOMEDICAL, INC. \DE\

Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.

This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.

Reported figures

Financial summary

Revenue FY2019
$557.6M
Net income
-$38.7M
Total assets
$239.3M
Market cap
$211.2M
Gross margin
31.3%
Operating margin
-13.4%
Net margin
-30.0%

Source: SEC EDGAR · updated Jun 7, 2026

Multi-year

Revenue & profit trend

Revenue Net income
FY 2025

Financial statements

Income statement

Revenue
$128.9M
Cost of revenue
$88.6M
Gross profit
$40.3M
Operating expenses
$57.5M
Operating income
-$17.2M
Income tax
$43.0K
Net income
-$38.7M
EPS (basic)
$-1.27
EPS (diluted)
$-1.27

Balance sheet

Total assets
$239.3M
Current assets
$85.7M
Total liabilities
$191.9M
Current liabilities
$30.2M
Shareholders’ equity
$1.3M

Cash flow

Operating cash flow
-$206.0K
Investing cash flow
-$6.4M
Financing cash flow
$6.4M
Net cash flow
-$197.0K

Statements via Polygon.io (SEC filings)

NASDAQ: LFCR
$5.57 -1.07%

15-minute delayed · data by Polygon.io

Past year

$3.66 $8.82

52-week range

Market cap
$211.2M
EPS (diluted)
$-1.27
Shares outstanding
37.9M
Open
Day range
Prev close
Volume
IPO date
Feb 15, 1996

Market data by Polygon.io · prices are 15-minute delayed

Auto-generated

At a glance

  • Reported a net loss of $38.7M in FY2019.
  • Revenue grew 25% from FY2023 to FY2025.
  • Gross margin of 31.3%, net margin -30.0%.
  • Trading 37% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review LIFECORE BIOMEDICAL, INC. \DE\.

Write a review
Newsroom

News about LIFECORE BIOMEDICAL, INC. \DE\

News & sentiment via Polygon.io

Explore

Similar companies

Browse all →